Skip to content
IP + Technology Law
Alistair J. McIntyre - Associate - San Diego

Alistair J. McIntyre

Associate
San Diego
alistair.mcintyre@knobbe.com
858-707-4000
vcard iconDownload vCard

Overview

Alistair is an associate in our San Diego Office. His practice includes patent prosecution and portfolio management (domestic and international), competitive landscape analysis, and patentability, infringement, and invalidity investigations. Alistair represents clients ranging from startups to multinational corporations within a variety of technological fields, including biotechnology, medical devices, electronics, and pharmaceuticals.

Alistair received his J.D. from UC Berkeley Law, where he was a member of and contributor to the Berkeley Technology Law Journal and involved with the Samuelson Law, Technology & Public Policy Clinic. Prior to law school, Alistair worked in the biotech industry for three years. Working within R&D groups, Alistair developed molecular assays and assay components at a couple of startups before moving to Illumina, where his work focused on developing tests and setting specifications for use in quality control.

As a former bioengineer, Alistair has the ability to quickly understand new technologies and identify key IP issues.

Alistair joined the firm in 2021.

Education

  • University of California - Berkeley (J.D., 2021), Berkeley Technology Law Journal; Samuelson Law, Technology & Public Policy Clinic
  • University of California - San Diego (M.S. Bioengineering, 2015), Bioengineering Graduate Society
  • University of Minnesota (B.E. Biomedical Engineering, 2013), Cum Laude

Bar Admissions

  • U.S. Patent and Trademark Office

News & Insights

Articles

Latest Updates and News

Blog - Biotechnology
Mar 2025
Two Bills Introduced to Target “Patent Thickets” and “Product Hopping”
On March 17, 2025, a bipartisan group of senators introduced two bills intended to decrease the cost of prescription drugs. The sponsors include Chuck Grassley (R-Iowa), John Cornyn (R-Texas), Richard...
Blog - Biotechnology
Nov 2024
CDRH Announces Pilot Program to Improve Recall Communication
On November 21, 2024, the FDA’s Center for Devices and Radiological Health (CDRH) announced a pilot communications program for improving the timeliness for communicating high-risk recalls.[1] The CDRH intends for...
Blog - Medical Devices & Procedures
Sep 2024
Test Anxiety: FDA Issues Warning Letters to Test Laboratories
The Food and Drug Administration (FDA) recently issued warning letters to two third-party nonclinical testing laboratories. The FDA cited the laboratories for “oversight failures and animal care violations that raise concerns with the quality and integrity of data generated.” The press release can be found here.
Blog - Biotechnology
Sep 2024
Science Group Sues FDA Over New Laboratory-Developed Test Rule
On August 19, 2024, the Association for Molecular Pathology (AMP) sued the FDA to challenge a new rule that allows the FDA to regulate laboratory developed tests (LDTs). The rule, which became effective on July 5, 2024, explicitly categorizes in vitro LDTs intended for clinical use as medical devices, placing such LDTs within the purview of the FDA. The complaint was filed in the Southern District of Texas. AMP’s suit follows another suit filed by a trade association, the American Clinical Laboratory Association, targeting the same rule.
Blog - Biotechnology
May 2024
FDA Issues Final Rule on Laboratory-Developed Tests
On April 29, 2023, the FDA announced a final rule on regulation of laboratory developed tests (LDTs).[1] The rule explicitly categorizes in vitro diagnostic products (IVDs) intended for clinical use as medical devices, which are within the purview of the FDA.[2] The final rule will publish on May 6, 2024.[3] Until then, the unpublished version is available. [4]
Blog - Medical Devices & Procedures
Mar 2024
New Ethylene Oxide Regulations May Raise Cost of Sterilization
Last week, the Environmental Protection Agency (EPA) announced new regulations to reduce ethylene oxide emissions. According to the EPA’s press release, the new regulations are “the strongest measures in U.S. history to reduce emissions of [ethylene oxide], one of the most potent cancer-causing chemicals.” The new regulations can be found here. The press release states that the regulations will affect “nearly 90 commercial sterilization facilities . . . owned and operated by approximately 50 companies.” The regulations require installation of air pollution controls to reduce emissions by more than 90%. The regulations are intended to reduce lifetime cancer risk for those living nearby sterilization facilities.